Scenic is unlocking the ground-breaking science of genetic modifiers to develop breakthrough therapies - we call this approach - Evolution Inspired Medicine

Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene.

As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of genetic modifiers and has already identified a number of novel genetic modifiers for over a dozen inherited diseases.

This approach is enabling the development of disease modifying therapeutics for devastating diseases including inherited rare diseases and cancer.

The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University. Through licensing from academic partners, and through our own strategy, Scenic has secured a strong Intellectual Property, covering its platform technology, its therapeutic targets, and composition of chemical matter/combinations for potential drug interventions.

Learn more about Scenic’s approach through this animation.

Scenic Biotech is headquartered in Amsterdam, the Netherlands.

Investors
Scenic Biotech has raised €8.0M in a Series A Financing backed by a Dutch-UK syndicate of Venture Capitalist investors that include BioGeneration Ventures, Inkef Capital, and Oxford Sciences Innovation. It has received €3.1 M non-dilutive Innovation Credit funding from the Dutch government RVO agency of the Ministry of Economic Affairs and Climate Policy.

Legal note – ‘Scenic Biotech’ refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV.

Oscar Izeboud

Chief Executive Officer

Oscar joined Scenic Biotech in July 2020. He spent the previous 14 years in investment banking in Life Sciences at Kempen&Co and NIBC Bank. As Managing Director he was responsible for the execution of numerous ipo’s, capital market-, and m&a transactions across Europe and the USA. Before that, he worked in various commercial and business development roles in biotech and pharma. Oscar has a MSc in Biopharmaceutical Sciences from Leiden University, and a PhD in Pharmacology from Utrecht University.

Amsterdam – Sebastian Nijman en Thijn Brummelkamp van scenic biotech.

Sebastian Nijman

Founder & Chief Scientific Officer

Sebastian obtained his PhD from The Netherlands Cancer Institute and was a postdoctoral fellow at the Broad Institute of Harvard and the M.I.T.. He was group leader at the Research Center for Molecular Medicine in Vienna from 2007-2014 and a member of the Young Academy of the Austrian Academy of Sciences. In 2010 he co-founded Haplogen GmbH and was its COO until 2014. At Haplogen, he initiated a partnership with Horizon Discovery, and co-led the subsequent $12Mio acquisition of Haplogen Genomics.

Sanne Weijzen

Sanne Weijzen

Chief Operations Officer

Sanne performed her Ph.D. research at the Cardinal Bernardin Cancer Center in Chicago (USA) and Leiden University (NL) and did her post-doc at the Utrecht University Medical Center (the Netherlands). In 2006, she joined Aglaia BioMedical Ventures, a venture capital firm investing in early stage oncology companies, where she became a partner in 2011. Between 2014 and 2017, she supported early stage biotech companies with financing rounds, business strategy, IP management and license negotiations as a consultant. Sanne joined Scenic Biotech in 2017 as COO.

Ulrich Grau

Ulrich Grau

Board of Directors (Chairman, independent)

Ulrich Grau has been appointed chairman of Scenic in July 2018. He serves also as chairman of i-novion and on the Boards of Affimed and Thermosome. He has over 35 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, he was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, he served as CSO at Enzon, and as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included adalimumab (Humira®). The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. The long-acting insulin Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Ulrich received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.

Amsterdam – Thijn Brummelkamp van scenic biotech.

Thijn Brummelkamp

Founder & Board of Directors

Thijn received his PhD from the Netherlands Cancer Institute (cum laude) and was appointed as a Fellow in 2004 at the Whitehead Institute for Biomedical Research in Cambridge in the United States. He was listed among the world’s top innovators under the age of 35 by M.I.T.’s Technology Review Magazine (2005) and was awarded the prestigious EMBO Gold Medal (2013). Thijn currently is a group leader at The Netherlands Cancer Institute, Professor of Experimental Genetics at Utrecht University and Adjunct PI at the Research Center for Molecular Medicine (CeMM) in Vienna. Thijn is also a co-founder of Haplogen GmbH and a member of their Scientific Advisory Board.

Foto Roel

Roel Bulthuis

Board of Directors

Roel Bulthuis is a Managing Partner and head of Healthcare investments at INKEF Capital. Roel combines close to 20 years of experience across venture capital, pharma business development and healthcare investment banking. Prior to joining INKEF he was SVP and Managing Director of M-Ventures which he created and developed into a leading CVC platform with four funds investing in therapeutics, life science technologies, advanced materials and technology enabled healthcare. Prior to that, he served in senior positions in global business development and M&A at Merck Serono and in the healthcare investment banking team at Fortis Bank. In 2016, ‘17 and ‘18, Roel was selected by GCV Magazine for its list of the world’s most influential corporate VCs. Roel is a Kauffman Fellow and passionate about continuously improving the role VC’s play in supporting entrepreneurship. Roel holds an Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.

Amsterdam – Scenic Biotech

Alexandra Glucksmann

Board of Directors

Alexandra holds a Ph.D. with honors from the University of Chicago and was a post-doctoral fellow at the M.I.T.. She spent 13 years at Millennium Pharmaceuticals, ultimately serving as Vice President. She was Senior VP at Cerulean Pharma. Most recently, Alexandra served as founding chief operating officer of Editas Medicine Inc.. Alexandra is currently President and CEO at Cedilla Therapeutics and serves on the board of Women in the Enterprise of Science and Technology (WEST).

thr20180411-0003-2zw

Edward van Wezel

Board of Directors

Edward is Founder and Managing Partner at BioGeneration Ventures (BGV) a venture capital firm focused on building new life sciences ventures in Europe. He currently serves on several supervisory boards and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca).

ucianescarlett_BW

Uciane Scarlett

Board of Directors, observer

Uciane is Principal at OSI. She was previously an Associate and EiR at Atlas Venture, where she was on the board of Quench Bio, Dyne Therapeutics, and Navitor. She also operated within the gene/cell therapy companies Korro Bio and AVROBIO. Prior to joining Atlas, Uciane was the Director of BD & Strategy at Compass Therapeutics, a preclinical stage I-O/immunology start-up. Prior to Compass, she was manager at Clarion Healthcare, a life science strategy consultancy. Uciane holds a PhD in cancer immunology from Dartmouth College. At OSI, Uciane currently represents OSI as an observer on the boards of PepGen and MiroBio.

stephen-friend

Stephen Friend

Scientific Advisory Board

Stephen is Chairman of Sage Bionetworks, President and co-founder of 4YouandMe, former Director at Apple Inc., Senior VP at Merck & Co, and co-founder of Rosetta Inpharmatics. Dr Friend has held faculty positions at Harvard Medical School, Massachusetts General Hospital, The University of Washington, and Mt Sinai Hospital. Stephen is a world leader in genetics oncology and health informatics.

Chas Bountra

Chas Bountra

Scientific Advisory Board

Chas is Chief Scientist of the Structural Genomics Consortium, Professor at the Univ. of Oxford and Imperial College London. He is the former VP and Head of Biology at GSK. At GSK he was involved in the development of over 40 clinical candidates and the launch of alosetron. Dr Bountra is on the SAB of Carrick Tx, Spinifex Pharma, Axol Bioscience, Tekcapital and IP Asset Ventures. Chas is a world leader in drug discovery and development.

Ton Schumacher

Ton Schumacher

Scientific Advisory Board

Ton is a Group leader at the Netherlands Cancer Institute and Professor of Immunotechnology at Leiden University. Dr Schumacher is Co-founder of The T-Cell Factory (acquired by Kite Pharma/Gilead), AIMM Therapeutics, and Neon Therapeutics. Ton is a world leader in tumor neoantigens and immuno-oncology.